By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nordic Nanovector 

Kjelsåsveien 168 B

  Oslo  0884  Norway
Phone: 47-22-18-33-01 Fax: 47-22-58-00-07


Company News
Nordic Nanovector: Invitation To Fourth Quarter And Full Year 2016 Results Presentation And Webcast 2/22/2017 7:40:52 AM
Nordic Nanovector: Share Capital Increase Registered 2/2/2017 10:46:40 AM
Nordic Nanovector: Share Options Granted, Including Options To Primary Insiders 2/2/2017 10:25:21 AM
Nordic Nanovector: Mandatory Notification Of Trade - Primary Insiders 12/9/2016 11:09:23 AM
Nordic Nanovector: Betalutin In Combination With Rituximab Demonstrates Synergistic Anti-Tumour Effect In Preclinical Non-Hodgkin Lymphoma Model 12/6/2016 9:42:59 AM
Nordic Nanovector: Single-Dose Betalutin Shows Promising Efficacy, Improved Duration Of Response And Favourable Safety In Relapsed NHL Patients 12/5/2016 9:59:28 AM
Nordic Nanovector– Results For Third Quarter 2016 11/23/2016 9:12:18 AM
Nordic Nanovector Appoints Lisa Rojkjaer, MD As Chief Medical Officer 11/15/2016 9:51:17 AM
Safety Review Committee For Nordic Nanovector's Lymrit 37-01 Trial Recommends Dose Escalation To 20 MBq/kg With Betalutin 11/4/2016 3:52:08 PM
Nordic Nanovector: Results From Preclinical Studies Of Betalutin In Combination With Rituximab In Non-Hodgkin Lymphoma Model To Be Presented At American Society of Hematology 11/3/2016 9:32:50 AM